ANDA 202653, held by Lupin. Gatifloxacin.
As of Nov 16, 2026, ANDA 202653 (Gatifloxacin), held by Lupin, was first approved by FDA on Aug 28, 2013, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 28, 2013 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Gatifloxacin0.5% · solution/drops;ophthalmic | Gatifloxacin | Discontinued |
| Oct 2, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 28, 2013 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters